Liposomal delivery of proteins and peptides

Expert Opinion on Drug Delivery

Volumn 9, Issue 12, 2012, Pages 1489-1503

  Swaminathan, Janani ^a   Ehrhardt, Carsten ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Biopharmaceuticals; Calcitonin; Insulin; Interleukins; Lipid vesicles; Vasoactive intestinal peptide

Indexed keywords

CALCITONIN; DRUG CARRIER; INSULIN; INTERLEUKIN 2; INTERLEUKIN DERIVATIVE; LIPOSOME; OSTORA; SALCATONIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG COST; DRUG FORMULATION; DRUG MARKETING; DRUG SYNTHESIS; DRUG USE; ENCAPSULATION; HUMAN; IN VIVO STUDY; LIPOSOMAL DELIVERY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SURFACE CHARGE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION ROUTES; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; LIPOSOMES; PEPTIDES; PROTEINS;

EID: 84869773544     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.735658     Document Type: Review

References (109)

1. Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci 2010;99:2557-75
2. Swaminathan J, Ehrhardt C. Chapter 14-Liposomes for pulmonary drug delivery. Control Pulm Drug Deliv 2011;313-34
3. Storm G, Crommelin DJA. Liposomes: quo vadis? PSTT 1998;1:19-31
4. Weiner AL. Liposomes for protein delivery: selecting manufacture and development processes. Immunomethods 1994;4:201-9 (Pubitemid 24318702)
5. Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 1986;40:333-45 (Pubitemid 16040787)
6. Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 2002;22:129-50 (Pubitemid 35222729)
7. Stark B, Andreae F, Mosgoeller W, et al. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation. Eur J Pharm Biopharm 2008;70:153-64
8. Adibzadeh M, Weder HG, Rehbein A, et al. Activity of liposomal interleukin-2 in vitro. Mol Biother 1992;4:24-8
9. Kato Y, Hosokawa T, Hayakawa E, Ito K. Influence of liposomes on tryptic digestion of insulin II. Bio Pharm Bull 1993;16:740-4 (Pubitemid 23288160)
10. Corona-Ortega T, Rangel-Corona R, Hernandez-Jimenez M, et al. Characterisation of cationic liposomes having IL-2 expressed on their external surface and their affinity to cervical cancer cells expressing the. IL-2 receptor. J Drug Target 2009;17:496-501
11. Law SL, Shih CL. Characterisation of calcitonin-containing liposome formulations for intranasal delivery. J Microencapsul 2001;18:211-21 (Pubitemid 32177839)
12. Hwang SH, Maitani Y, Qi X, et al. Remote loading of diclofenac, insulin and fluorescein isothiocyanate labelled insulin into liposomes by pH and acetate gradient methods. Int J Pharm 1999;179:85-95 (Pubitemid 29115063)
13. Hwang SH, Maitani Y, Takayama K, Nagai T. High entrapment of insulin and bovine serum albumin into neutral and positively-charged liposomes by the remote loading method. Chem Pharm Bull (Tokyo) 2000;48:325-9 (Pubitemid 30187242)
14. Immordino ML, Dosio F, Cattel L. Stealth liposome: review of the basic science, rationale and clinical applications, existing and potential. Int J Nanomed 2006;1(3):297-315
15. Park S, Choi SG, Davaa E, Park J. Encapsulation enhancement and stabilisation of insulin in cationic liposomes. Int J Pharm 2011;415:267-72
16. Kedar E, Gur H, Babai I, et al. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long circulating liposomes. J Immunother 2000;23:131-45 (Pubitemid 30079834)
17. Arien A, Tolume-Henry N, Dupuy B. Cholate-induced disruption of calcitonin-loaded liposomes: formation of trypsin-resistant lipid-calcitonin- cholate complexes. Pharm Res 1995;12:1289-92
18. Stark B, Debbage P, Andreae F, et al. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. Biochim Biophys Acta 2007;1768:705-14 (Pubitemid 46275600)
19. Neville ME, Boni LT, Pflug LE, et al. Biopharmaceutics of liposomal interleukin-2, Oncolipin. Cytokine 2000;12:1691-701
20. Joffret ML, Morgeaux S, Laclerc C, et al. Enhancement of interleukin-2 activity by liposomes. Vaccine 1990;8:385-9 (Pubitemid 20264818)
21. Degim Z, Unal N, Essiz D, Abbasoglu U. The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci 2004;75:2819-27 (Pubitemid 39349268)
22. Maitani Y, Asano S, Takahashi S, et al. Permeability of insulin entrapped in liposome through the nasal mucosa of rabbits. Chem Pharm Bull (Tokyo) 1992;40:1569-72
23. Song K, Chung S, Shim C. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release 2005;106:298-308 (Pubitemid 41187439)
24. Khanna C, Waldrep JC, Anderson PM, et al. Nebulised interleukin-2 liposomes: aerosol characteristics and biodistribution. J Pharm Pharmacol 1997;49:960-71 (Pubitemid 27478387)
25. Kim ST, Lee K, Park H, et al. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. J Gene Med 2009;11:26-37
26. Mayer A, Andratschke M, Pauli C, et al. Liposomal transfection of squamous carcinoma cells of the head and neck with IL-2 and B7 plasmids including an autologous immune response in vitro. Anticancer Res 2005;25:3917-23 (Pubitemid 41665164)
27. Available from: http://www. tarsatherapeutics.com/Products/calcitonin. html
28. Available from: www.emisphere.com/pdfs/Drug-Dlvy-Techy-QA-May-08.pdf
29. Available from: http://www.rttnews.com/1733477/emisphere-says-second- phase-iiistudy-of-oral-calcitonin-did-not-meetendpoints. aspx
30. Hess DR. Nebuliser: principle and performance. Respir Care 2000;45:609-22
31. Kling J. Inhaled insulin's last gasp? Nat Biotech 2008;26:479-80 (Pubitemid 351668021)
32. Available from: www.pharma.us.novartis. com/product/pi/pdf/miacalcin- nasal.pdf
33. Kumar R, Philip A. Modified transdermal technologies: breaking the barriers of drug permeation via the skin. Trop J Pharm Res 2007;6:633-44
34. Jain N, Talegonkar S, Jain NK. New ways to enter the blood stream: emerging strategies in transdermal drug delivery. Pharm Rev 2004;41-59
35. Available from: http://www. dietpillswatchdog.com/are-diet-patches- aseffective-as-diet-pills/
36. Diociaiuti M, Polzi LZ, Valvo L, et al. Calcitonin forms oligomeric pore-like structures in lipid membranes. Biophys J 2006;91:2275-81 (Pubitemid 44352409)
37. Bradshaw JP. Phosphatidylglycerol promotes bilayer insertion of salmon calcitonin. Biophys J 1997;72:2180-6 (Pubitemid 27184445)
38. Ntimenou V, Mourtas S, Christodoulakis EV, et al. Stability of protein-encapsulating DRV liposomes after freeze-drying: a study with BSA and t-PA. J Liposome Res 2006;16:403-16 (Pubitemid 44949889)
39. Koromila G, Michanetzis GP, Missirlis YF, Antimisiaris SG. Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: effect on haemocompatibility. Biomaterials 2006;27:2525-33 (Pubitemid 43113277)
40. Vangala A, Bramwell VW, McNeil S, et al. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release 2007;119:102-10 (Pubitemid 46561543)
41. Antimisiaris SG. Preparation of DRV liposomes. Methods Mol Biol 2010;605:51-75
42. Stevenson RW, Patel HM, Parsons JA, Ryman BE. Prolonged hypoglycaemic effect in diabetic dogs due to subcutaneous administration of insulin in liposomes. Diabetes 1982;31:506-11 (Pubitemid 12119336)
43. Gao XP, Noda Y, Rubinstein I, Paul S. Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure. Life Sci 1994;54:PL247-52 (Pubitemid 2062827)
44. Refai E, Jonsson C, Andersson M, et al. Biodistribution of liposomal 131I-VIP in rat using gamma camera. Nucl Med Biol 1999;26:931-6 (Pubitemid 30047163)
45. Konno H, Maruo Y, Matin AF, et al. Effect of liposomal interleukin-2 on ascites-forming rat hepatoma. J Surg Oncol 1992;51:33-7
46. Cao X, Wang Q, Ju DW, et al. Efficient inducation of local and systemic antitumour immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene. J Exp Clin Cancer Res 1999;18:191-200 (Pubitemid 29359403)
47. Kanaoka E, Takahashi K, Yoshikawa T, et al. Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice. Drug Dev Ind Pharm 2003;29:1149-53 (Pubitemid 37499550)
48. Rangel-Corona R, Corona-Ortega T, del Rio-Ortiz I, et al. Cationic liposomes bearing IL-2 on their external surface induced mice leukocytes to kill human cervical cancer cells in vitro and significantly reduced tumour burden in immunodepressed mice. J Drug Target 2011;19:79-85
49. Kabay B, Kocaefe YC, Baykal A, et al. Liposome-mediated intraperitoneal interleukin-10 gene transfer increases survival in cecal litigation and puncture model of sepsis. Shock 2006;26:37-40 (Pubitemid 44297004)
50. Petkowicz J, Byra A, Szumilo T. The hypoglycaemic response of diabetic rats to insulin-liposomes. Acta Physiol Pol 1990;41:97-103
51. Kanaoka E, Takahashi K, Yoshikawa T, et al. A novel and simple type of liposome carrier for recombinant interleukin-2. J Pharm Pharmacol 2001;53:295-302 (Pubitemid 32229188)
52. Fukunaga M, Miller MM, Hostetler KY, Deftos LJ. Liposome entrapment enhances the hypocalcaemic action of parenterally administered calcitonin. Endocrinology 1984;115:757-61 (Pubitemid 14054142)
53. Cabanes A, Even-Chen S, Zimberoff J, et al. Enhancement of anti-tumour activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin-2. Clin Cancer Res 1999;5:687-93 (Pubitemid 29131981)
54. Kim A, Yun M, Oh Y, et al. Pharmacodynamics of insulin in polyethylene glycol-coated liposomes. Int J Pharm 1999;180:75-81 (Pubitemid 29131445)
55. Rubinstein I, Ikezaki H, Onyuksel H. Intratracheal and subcutaneous liposomal VIP normalises arterial pressure in spontaneously hypertensive hamsters. Int J Pharm 2006;316:144-7 (Pubitemid 43765699)
56. Kedar E, Braun E, Rutkowski Y, et al. Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilised liposomes: immunomodulatory and anti-tumour activity in mice. J Immunother Emphasis Tumour Immunol 1994;16:115-24 (Pubitemid 24303422)
57. Gursel M, Gregoriadis G. The immunological co-adjuvant action of liposomal interleukin-2: the role of mode of localisation of the cytokine and antigen in the vesicles. J Drug Target 1997;5:93-8 (Pubitemid 28149571)
58. Johnston D, Reynolds SR, Bystryn J. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice. Cancer Immunol Immunother 2006;55:412-19 (Pubitemid 43076893)
59. Duits AJ, van Puijenbroek A, Vermeulen H, et al. Immunoadjuvant activity of a liposomal IL-6 formulation. Vaccine 1993;11:777-81 (Pubitemid 23190666)
60. Gursel M, Gregoriadis G. Interleukin-15 acts as an immunological co-adjuvant for liposomal antigen in vivo. Immunol Lett 1997;55:161-5 (Pubitemid 27186778)
61. Dhillon NK, Dhillon S, Chebloune Y, et al. Therapy of 'SHIV' infected macaques with liposomes delivering antisense interleukin-4 DNA. AIDS 2006;20:1125-30 (Pubitemid 43786100)
62. Simpson-Abelson MR, Purohit VS, Pang WM, et al. IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumour microenvironments. Clin Immunol 2009;132:71-82
63. Charoensit P, Kawakami S, Higuchi Y, et al. Enhanced growth inhibition of metastatic lung tumours by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice. Cancer Gene Ther 2010;17:512-22
64. Hashimoto A, Kawada J. Effects of oral administration of positively charged insulin liposomes on alloxan diabetic rats: preliminary study. Endocrinol Jpn 1979;26:337-44 (Pubitemid 10221210)
65. Kisel MA, Kulik LN, Tsybovsky IS, et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm 2001;216:105-14 (Pubitemid 32232100)
66. Choudhari KB, Labhasetwar V, Dorle AK. Liposomes as a carrier for oral administration of insulin: effect of formulation factors. J Microencapsul 1994;11:319-25 (Pubitemid 24148441)
67. Muramatsu K, Maitani Y, Nagai T. Dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols and cholesterol as a carrier for the oral administration of insulin in rats. Bio Pharm Bull 1996;19:1055-88
68. Takeuchi H, Yamamoto H, Niwa T, et al. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res 1996;13:896-901 (Pubitemid 26227747)
69. Iwanaga K, Ono S, Narioka K, et al. Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J Pharm Sci 1999;88:248-52 (Pubitemid 29084739)
70. Ramadas M, Paul W, Dileep KJ, et al. Lipoinsulin encapsulated alginate-chitosan capsules: intestinal delivery in diabetic rats. J Microencapsul 2000;17:405-11 (Pubitemid 30420823)
71. Wu ZH, Ping QN, Wei Y, Lai JM. Hypoglycaemic efficacy of chitosan-coated insulin liposomes after oral administration in mice. Acta Pharmacol Sin 2004;25:966-72 (Pubitemid 38915458)
72. Degim IT, Gumusel B, Degim Z, et al. Oral administration of liposomal insulin. J Nanosci Nanotechnol 2006;6:2945-9 (Pubitemid 44579966)
73. Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release 2003;86:235-42 (Pubitemid 36084273)
74. Thongborisute J, Takeuchi H, Yamamoto H, Kawashima Y. Properties of liposomes coated with hydrophobically modified chitosan in oral liposomal drug delivery. Pharmazie 2006;61:106-11 (Pubitemid 43293891)
75. Das N, Basu MK, Das MK. Oral application of insulin encapsulated liposomes. Biochem Int 1988;16:983-9
76. Goto T, Morishita M, Nishimura K, et al. Novel mucosal insulin delivery systems based on fusogenic liposomes. Pharm Res 2006;23:384-91 (Pubitemid 43237868)
77. Katayama K, Kato Y, Onishi H, et al. Double liposomes: hypoglycaemic effects of liposomal insulin on normal rats. Drug Dev Ind Pharm 2003;29:725-31 (Pubitemid 36899878)
78. Yamabe K, Kato Y, Onishi H, Machida Y. Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. J Control Release 2003;89:429-36 (Pubitemid 36555902)
79. Ebato Y, Kato Y, Onishi H, et al. In vivo efficacy of a novel double liposome as an oral dosage form of salmon calcitonin. Drug Devel Res 2003;58:253-7 (Pubitemid 36555060)
80. Suzuki H, Noda Y, Paul S, et al. Encapsulation of vasoactive intestinal peptide into liposomes: effects on vasodilatation in vivo. Life Sci 1995;57:1451-7
81. Suzuki H, Noda Y, Gao XP, et al. Encapsulation of VIP into liposomes restores vasorelaxation in hypertension in situ. Am J Physiol 1996;271:H282-7
82. Sejourne F, Suzuki H, Alkan-Onyuksel H, et al. Mechanisms of vasodilatation elicited by VIP in sterically stabilised liposomes in vivo. Am J Physiol 1997;273(1-2):R287-92 (Pubitemid 27345582)
83. Ikezaki H, Paul S, Alkan-Onyuksel H, et al. Vasodilatation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch. Am J Physiol 1998;275:R56-62
84. Ikezaki H, Onyuksel H, Rubinstein I. Liposomal VIP attenuates phenylephrine and ANG II induced vasoconstriction in vivo. Am J Physiol 1998;275:R588-95
85. Onyuksel H, Ashok B, Dagar S, et al. Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity. Peptides 2003;24:281-6 (Pubitemid 36369348)
86. Huang Y, Wang C. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006;113:9-14 (Pubitemid 43818162)
87. Bi R, Shao W, Wang Q, Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target 2008;16:639-48
88. Khanna C, Hasz DE, Klausner JS, Anderson PM. Aerosol delivery of interleukin-2 liposomes is non-toxic and biologically effective: canine studies. Clin Cancer Res 1996;2:721-34 (Pubitemid 26135341)
89. Karathanasis E, Bhavane R, Annapragada AV. Triggered release of inhaled insulin from the agglomerated vesicles: pharmacodynamic studies in rats. J Control Release 2006;113:117-27 (Pubitemid 43928146)
90. Karathanasis E, Bhavane R, Annapragada AV. Glucose-sensing pulmonary delivery of human insulin to the systemic circulation of rats. Int J Nanomedicine 2007;2:501-13 (Pubitemid 350047793)
91. Khanna C, Anderson PM, Hasz DE, et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997;79:1409-21 (Pubitemid 27143249)
92. Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs 2000;11:555-63
93. Ten RM, Anderson PM, Zein NN, et al. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol 2002;2:333-44 (Pubitemid 34075422)
94. Chono S, Fukuchi R, Seki T, Morimoto K. Aerosolised liposomes with dipalmitoylphosphatidylcholine enhance pulmonary insulin delivery. J Control Release 2009;137:104-9
95. Goerke J. Pulmonary surfactant: functions and molecular composition. Biochim Biophys Acta 1998;1408:79-89 (Pubitemid 28517859)
96. Muramatsu K, Maitani Y, Takayama K, Nagai T. The relationship between the rigidity of the liposomal membrane and the absorption of insulin after nasal administration of liposomes modified with an enhancer containing insulin in rabbits. Drug Dev Ind Pharm 1999;25:1099-105 (Pubitemid 29477867)
97. Chen M, Li X, Zhou Y, et al. Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Peptides 2009;30:1288-95
98. Law SL, Huang KJ, Chou VHY, Cherng JY. Enhancement of nasal absorption of calcitonin loaded in liposomes. J Liposome Res 2001;11:165-74 (Pubitemid 33096376)
99. Jain AK, Chalasani KB, Khar RK, et al. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J Drug Target 2007;15:417-27 (Pubitemid 47073057)
100. du Plessis LH, Lubbe J, Strauss T, Kotze AF. Enhancement of nasal and intestinal calcitonin delivery by the novel pheroid fatty acid based delivery system and by N-trimethyl chitosan chloride. Int J Pharm 2010;385:181-6
101. Abraham E, Shah S. Intranasal immunisation with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. J Immunol 1992;149:3719-26
102. Lajavardi L, Bochot A, Camelo S, et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci 2007;48:3230-8 (Pubitemid 351261168)
103. Camelo S, Lajavardi L, Bochot A, et al. Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Mol Vis 2007;13:2263-74 (Pubitemid 350268733)
104. Camelo S, Lajavardi L, Bochot A, et al. Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis. J Ocul Pharmacol Ther 2009;25:9-21
105. Lajavardi L, Camelo S, Agnely F, et al. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic gel for uveitis. J Control Release 2009;139:22-30
106. Guo J, Ping Q, Zhang L. Transdermal delivery of insulin in mice by using lecithin vesicles as a carrier. Drug Deliv 2000;7:113-16 (Pubitemid 30399620)
107. Li J, Li X, Zhang Y, et al. Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. J Gene Med 2010;12:481-90
108. Kajimoto K, Yamamoto M, Watanabe M, et al. Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis. Int J Pharm 2011;403:57-65
109. Suzuki R, Namai E, Oda Y, et al. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release 2010;142:245-50